Results 161 to 170 of about 1,292,876 (289)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Pattern of Musculoskeletal Pain Among Patients With Type 2 Diabetes: A Cross-Sectional Study. [PDF]

Cureus
Mohsin Raza M, Sajjad S, Ikram W, Manan A, Khan S, Ullah M.   +5 more
europepmc   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Key determinants for successful lifestyle change to address chronic musculoskeletal pain: The patient's perspective. [PDF]

PM R
Snider EM, Gou CY, Martin A, Ito KE, Hunt DM, Cheng AL.   +5 more
europepmc   +1 more source

Per‐ and Polyfluoroalkyl Substances and Knee Osteoarthritis: Data From the Osteoarthritis Initiative

Arthritis &Rheumatology, EarlyView.
Objective To examine whether concentrations of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS relate to incident knee osteoarthritis (KOA) and knee pain progression. Methods Among a case‐cohort sample from the OA Initiative (n = 1,878), we examined associations of serum concentrations of eight PFAS with odds of developing ...
Jeffrey B. Driban, Lisa B. Rokoff, Bing Lu, Timothy E. McAlindon, Charles B. Eaton, Mary B. Roberts, Diana Mathes, Colleen Lestician, Zhijin Carrie Xu, Zhihua Tina Fan, Shawn P. O'Leary, Ida K. Haugen, Jérémie Sellam, Alice Courties, Abby F. Fleisch   +14 more
wiley   +1 more source

Association of musculoskeletal pain with incidence and recurrence of cardiovascular disease: a longitudinal cohort in China. [PDF]

BMC Public Health
Chen Y, Sun S, Guo H, Yan L, Peng C, Deng Y, Cai Y, Zhu M.   +7 more
europepmc   +1 more source

Anti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Carbamylation, a nonenzymatic post‐translational modification, contributes to rheumatoid arthritis (RA) pathogenesis. Anti‐carbamylated protein antibodies (anti‐CarP) occur in around 50% of patients with RA and associate with greater joint damage. Neutrophil extracellular traps (NETs) are a major source of carbamylated autoantigens. We sought
Shuichiro Nakabo, Norio Hanata, Eduardo Patino‐Martinez, Ronald Holewinski, Ana Barrera‐Vargas, Javier Merayo‐Chalico, Scott A. Coonrod, David A. Fox, Mariana J. Kaplan, Carmelo Carmona‐Rivera   +9 more
wiley   +1 more source

Musculoskeletal pain in adolescents: a systematic review of predictive and associated factors. [PDF]

BMC Pediatr
Yazdani N, Shaygan M, Shojaei Zarghani S, Hemati M, Jamlimoghadam N.   +4 more
europepmc   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Multidimensional Characteristics of Musculoskeletal Pain and Risk of Falls Among Elderly Adults: The Cross-Sectional Evidence From CHARLS. [PDF]

Orthop Surg
Mei F, Li JJ, Lin J, Dong S, Zhang P, Xing D.   +5 more
europepmc   +1 more source